Brain metastases are common in melanoma patients and associated with poor prognosis.

Patients with brain metastases are under-represented in most clinical trials.

Evidence of clinical activity exists for both immunotherapy and MAP-kinase inhibitors.

Improved survival may be achieved also in melanoma patients with brain metastases.

These results support the inclusion in clinical trials of patients with brain metastases.